

EXPERTISE AND SERVICE PROVISION  
QUALITY OF LABORATORIES

EXTERNAL QUALITY ASSESSMENT  
IN VETERINARY DIAGNOSIS

**DEFINITIVE GLOBAL REPORT**  
**Proficiency Testing in Veterinary Diagnosis**  
**Maedi Visna Virus**  
**Serology**  
**SURVEY 2020/13**

**Sciensano/PT VET Maedi Visna/1-E**

Expertise and service provision  
Quality of laboratories  
J. Wytsmanstreet, 14  
1050 Bruxelles | Belgique

[www.sciensano.be](http://www.sciensano.be)

<b>COMMITTEE OF EXPERTS</b>
-----------------------------

<b>Sciensano</b>			
Secretariat		PHONE: 02/642.55.22	FAX: 02/642.56.45
Name scheme coordinator	Bernard China	PHONE: 02 642 53 85	
		e-mail: Bernard.China@sciensano.be	
Name alternate scheme coordinator	Arnaud Capron	PHONE:	
		e-mail: Arnaud.Capron@sciensano.be	
Experts	Institute		
<b>Ann Brigitte Cay</b>	<b>Sciensano</b>		
<b>Nick De Regge</b>	<b>Sciensano</b>		
<b>Marylene Tignon</b>	<b>Sciensano</b>		

A preliminary version of this report was submitted to the National reference laboratory: 01/02/2021

**Authorization to release the report:** By Bernard China, scheme coordinator, on 4/02/2021.

*Bernard China* 

All the reports are also available on our webpage:

[https://www.wiv-isp.be/QML/activities/PT%20VET/fr/originaux/rapports\\_annee.htm](https://www.wiv-isp.be/QML/activities/PT%20VET/fr/originaux/rapports_annee.htm)  
[https://www.wiv-isp.be/QML/activities/PT%20VET/nl/originaux/rapports\\_annee.htm](https://www.wiv-isp.be/QML/activities/PT%20VET/nl/originaux/rapports_annee.htm)

# TABLE OF CONTENTS

.....	3
<b>INTRODUCTION</b> .....	<b>4</b>
THE SAMPLES.....	4
SURVEY TIMELINE.....	5
<b>RESULTS</b> .....	<b>6</b>
1. SEROLOGY.....	6
1.1. <i>Results per sample</i> .....	6
1.2. <i>Used methods</i> .....	6
1.3. <i>Conclusion</i> .....	6
<b>ANNEXES</b> .....	<b>7</b>
ANNEX 1. QUANTITATIVE DATA FOR MAESI-VISNA SEROLOGY (NOT UNDER ACCREDITATION).....	7
ANNEX 2: ADDITIONAL INFORMATION.....	12
PRELIMINARY REPORT.....	12
GRAPHICAL REPRESENTATION.....	13

## **Introduction**

This survey was dedicated to the detection of antibodies specific to Maedi-Visna virus by ELISA.

## **The samples**

The samples were prepared by the National Reference Laboratory, Enzootic, vector-borne and bee diseases, Infectious diseases in animals Directorate, Sciensano.

5 serum samples (0,2 mL) were used: PT2020MAEELINS1, PT2020MAEELINS2, PT2020MAEELIPS1, PT2020MAEELIPS2 and PT2020MAEELIPS3

### **Homogeneity**

The homogeneity of the samples were tested on ten different aliquots by the NRL before the survey using ELITEST IDVET ELISA

The samples were considered as homogeneous.

### **Target Values**

The target value was determined by the NRL based on the homogeneity tests.

PT2020MAEELINS1 and PT2020MAEELINS2 are negative.

PT2020MAEELIPS1 and PT2020MAEELIPS2 are positive

PT2020MAEELIPS3 is considered as a doubtful (NEG/POS) sample.

### **Stability**

The stability was determined by comparison of the pre-survey results and the results obtained by the NRL during and after the survey. The samples were considered as stable.

### **The participants**

5 laboratories participated to the Maedi-Visna serological survey  
Sciensano ; Arsia , DGZ, Lavetan, LNCR (France).

## Randomisation and panel composition

Since a specific number has been assigned to each laboratory, the randomisation has been performed as follow:

	<b>Group 1 97505, 97507 and 97509</b>	<b>Group 2 97508 and 97510.</b>
<b>Sample Order</b>		
<b>MAESER2001</b>	PT2020MAEELINS1	PT20M20AEELIPS3
<b>MAESER2002</b>	PT2020MAEELINS2	PT20M20AEELIPS3
<b>MAESER2003</b>	PT2020MAEELIPS1	PT2020MAEELIPS1
<b>MAESER2004</b>	PT2020MAEELIPS2	PT2020MAEELIPS2
<b>MAESER2005</b>	PT2020MAEELINS2	PT2020MAEELIPS1
<b>MAESER2006</b>	PT2020MAEELINS1	PT2020MAEELIPS2
<b>MAESER2007</b>	PT2020MAEELIPS1	PT2020MAEELINS1
<b>MAESER2008</b>	PT20M20AEELIPS3	PT2020MAEELINS2
<b>MAESER2009</b>	PT20M20AEELIPS3	PT2020MAEELINS1
<b>MAESER2010</b>	PT2020MAEELIPS2	PT2020MAEELINS2
<b>MAESER2011</b>	PT2020MAEELINS2	PT2020MAEELINS1
<b>MAESER2012</b>	PT2020MAEELINS1	PT2020MAEELINS2

The panel was constituted of 12 samples of 0.2 ml

## **Survey Timeline**

Transfer of the samples from NRL to QL:6/11/2020

Randomization of the samples by QL:20/11/2020

Sending samples to participants: 4/11/2020. The samples were sent on dry ice.

Deadline for the results encoding: 24/12/2020

Preliminary report:18/12/2020

## **Results**

### **1. Serology**

The panel consisted 12 serum samples: 4 positive samples, 6 negative samples and 2 doubtful samples.

#### **1.1.Results per sample**

5 laboratories encoded results. One laboratory encoded 2 datasets. Therefore, 6 datasets were encoded.

Table R1. Results per sample

<b>Sample ID</b>	<b>Expected result</b>	<b>Number of repetitions (total results)</b>	<b>Observed result</b>
<b>PT2020MAEELINS1</b>	Negative	3 (18)	18 negative results
<b>PT2020MAEELINS2</b>	Negative	3 (18)	18 negative results
<b>PT2020MAEELIPS1</b>	Positive	2(12)	12 Positive results
<b>PT2020MAEELIPS2</b>	Positive	2(12)	12 Positive results
<b>PT2020MAEELIPS3</b>	Negative/positive	2(12)	12 Positive results

Globally, on 72 encoded results, 100% were considered as correct.

Interestingly, all the participant considered the T2020MAEELIPS3 sample as positive.

#### **1.2.Used methods**

IDvet-ID Screen MVV/CAEV Indirect:	2
HYPHEN BIOMED-ELITEST MVV/CAEV	3
LIFE TECHNOLOGIES-Ruminant MAEDI-VISNA/CAEV serum LSI:	1

The laboratory encoding 2 datasets used IDVET and Hyphen kits.

#### **1.3.Conclusion**

All the participants encoded correct results independently of the used method.

The sample PT2020MAEELIPS3 proposed by the NRL as doubtful was found as positive by all the participants and all the methods.

## ANNEXES

### Annex 1. Quantitative data for Maedi-Visna serology (not under accreditation)

SAMPLE PT2020MAEELINS1

Table A1. Quantitative normalized values (%)

Lab	97505	97507	97508	97509-1	97509-2	97510
<b>Method</b>	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	HYPHEN BIOMED ELITEST MVV/CAEV	IDvet-ID Screen MVV/CAEV Indirect	HYPHEN BIOMED ELITEST MVV/CAEV	LIFE TECHNOLOGIES Ruminant MAEDI-VISNA/CAEV serum LSI
<b>R1</b>	0.88	-0.053	-1.527	9.016	0.278	2.326
<b>R2</b>	1.12	-0.024	-1.045	8.782	0.081	0.000
<b>R3</b>	1.75	-0.022	-0.723	6.206	0.152	4.472
<b>mean</b>	1.25	-0.03	-1.10	8.00	0.17	2.27
<b>SD</b>	0.45	0.02	0.40	1.56	0.10	2.24
<b>CV</b>	36.3%	-52.9%	-36.8%	19.5%	58.6%	98.7%

Rn= repetition n




Figure A1. Boxplot dispersion of the results per participant for the sample NS1

SAMPLE PT2020MAEELINS2

Table A2. Quantitative normalized values (%)

Lab	97505	97507	97508	97509-1	97509-2	97510
<b>Method</b>	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	HYPHEN BIOMED ELITEST MVV/CAE	IDvet-ID Screen MVV/CAEV Indirect	HYPHEN BIOMED ELITEST MVV/CAEV	LIFE TECHNOLOGIES Ruminant MAEDI-VISNA/CAEV serum LSI
<b>R1</b>	1.44	-0.069	-1.527	8.431	0.060	0.000
<b>R2</b>	1.44	-0.061	-1.688	6.440	0.109	0.000
<b>R3</b>	2.39	-0.051	-1.688	8.197	0.202	21.170
<b>mean</b>	1.75	-0.06	-1.63	7.69	0.12	7.06
<b>SD</b>	0.55	0.01	0.09	1.09	0.07	12.22
<b>CV</b>	31.5%	-15.3%	-5.7%	14.1%	58.3%	173.2%

Rn= repetition n




Figure A2. Boxplot dispersion of the results per participant for the sample NS2



SAMPLE PT2020MAEELIPS1

Table A3. Quantitative normalized values (%)

Lab	97505	97507	97508	97509-1	97509-2	97510
<b>Method</b>	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	HYPHEN BIOMED ELITEST MVV/CAE V	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	LIFE TECHNOLOGIES Ruminant MAEDI-VISNA/CAEV serum LSI
<b>R1</b>	340.99	2.865	347.830	400.937	2.917	39.420
<b>R2</b>	336.76	2.864	356.511	400.937	2.796	38.100
<b>mean</b>	338.88	2.86	352.17	400.94	2.86	38.76
<b>SD</b>	2.99	0.00	6.14	0.00	0.09	0.93
<b>CV</b>	0.9%	0.0%	1.7%	0.0%	3.0%	2.4%

Rn= repetition n




Figure A2. Boxplot dispersion of the results per participant for the sample PS1

SAMPLE PT2020MAEELIPS2

Table A4. Quantitative normalized values (%)

Lab	97505	97507	97508	97509-1	97509-2	97510
<b>Method</b>	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	HYPHEN BIOMED ELITEST MVV/CAE V	IDvet-ID Screen MVV/CAE Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	LIFE TECHNOLOGIES Ruminant MAEDI-VISNA/CAEV serum LSI
<b>R1</b>	311.40	2.382	264.550	400.937	2.493	69.470
<b>R2</b>	299.84	2.538	284.486	389.578	2.454	65.410
<b>mean</b>	305.62	2.46	274.52	395.26	2.47	67.44
<b>SD</b>	8.18	0.11	14.10	8.03	0.03	2.87
<b>CV</b>	2.7%	4.5%	5.1%	2.0%	1.1%	4.3%

Rn= repetition n




Figure A2. Boxplot dispersion of the results per participant for the sample PS2

SAMPLE PT2020MAEELIPS3

Table A5. Quantitative normalized values (%)

Lab	97505	97507	97508	97509-1	97509-2	97510
<b>Method</b>	IDvet-ID Screen MVV/CAE V Indirect	HYPHEN BIOMED ELITEST MVV/CAE V	HYPHEN BIOMED ELITEST MVV/CAE	IDvet-ID Screen MVV/CAEV Indirect	HYPHEN BIOMED ELITEST MVV/CAEV	LIFE TECHNOLOGIES Ruminant MAEDI-VISNA/CAEV serum LSI
<b>R1</b>	308.61	1.124	88.183	389.578	1.938	86.760
<b>R2</b>	312.12	1.041	86.093	398.009	2.041	86.400
<b>mean</b>	310.37	1.08	87.14	393.79	1.99	86.58
<b>SD</b>	2.48	0.06	1.48	5.96	0.07	0.25
<b>CV</b>	0.8%	5.4%	1.7%	1.5%	3.7%	0.3%

Rn= repetition n




Figure A2. Boxplot dispersion of the results per participant for the sample PS3

## **Annex 2: additional information**

### **PRELIMINARY REPORT**

The preliminary report of this survey is available on our website via the following link:

[https://www.wiv-isp.be/QML/activities/PT%20VET/fr/originaux/rapports\\_annee.htm](https://www.wiv-isp.be/QML/activities/PT%20VET/fr/originaux/rapports_annee.htm)

The calendar for Proficiency Testing in Veterinary diagnosis is available on our website:


The link is:

[https://www.wiv-isp.be/QML/activities/external\\_quality/calendar/calender\\_PT%20VET/fr/Calendrier\\_2020-PT%20VET%202.htm](https://www.wiv-isp.be/QML/activities/external_quality/calendar/calender_PT%20VET/fr/Calendrier_2020-PT%20VET%202.htm)

## Graphical representation

Besides the tables with the results a "Box and whisker" plot is added. It contains the following elements for the methods with at least 6 participants:

- a rectangle ranging from percentile 25 ( $P_{25}$ ) to percentile 75 ( $P_{75}$ )
- a central line representing the median of the results ( $P_{50}$ )
- a lower limit showing the smallest value  $x > P_{25} - 1.5 * (P_{75} - P_{25})$
- an upper limit representing the largest value  $x < P_{75} + 1.5 * (P_{75} - P_{25})$
- all points outside this interval are represented by a dot.



### Corresponding limits in case of normal distribution

© Sciensano, Brussels 2021.

This report may not be reproduced, published or distributed without the consent of Sciensano. The laboratories' individual results are confidential. They are not passed on by Sciensano to third parties, nor to members of the Commission, the committees of experts or the working group EQA.

END